Bausch + Lomb Corporation BLCO
Nov 5, 2026, 1:43 PM EST
- YTD
- +17.04%
- 1 year
- +27.08%
- Market cap
- 7.16B
- Revenue (ttm)
- 5.42B
- Profit margin
- -2.05%
- EPS (ttm)
- -0.32
- Shares out
- 357.50M
- Forward P/E
- 17.27
- YTD return
- +17.04%
- 1-year return
- +27.08%
- Volume
- 403.30K
- Avg volume
- 591.48K
- Open
- 20.70
- Previous close
- 20.60
- Day's range
- 19.89 – 20.76
- 52-week range
- 14.44 – 21.36
- Beta
- 0.52
- Analysts
- Buy
- Price target
- 21.71 (+8.6%)
- Earnings date
- Feb 17, 2027
2Y +0.25 (+1.26%)
Key statistics
- Enterprise value
- 11.81B
- PEG ratio
- 0.89
- Price / sales
- 1.36
- Price / book
- 1.14
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 7.30%
- Free cash flow
- 404.38M
- Total cash
- 513.00M
- Total debt
- 5.10B
- Return on equity
- -1.58%
- Short % of float
- 5.55%
- 50-day average
- 17.46
- 200-day average
- 16.70
Analyst view
Consensus: buy
- Target (low)
- 18.00
- Target (mean)
- 21.71
- Target (high)
- 26.00
- Strong buy2
- Buy4
- Hold8
- Sell0
- Strong sell1
Next earnings
Feb 17, 2027
Expected Feb 17, 2027. Consensus EPS estimate 0.37014.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 17, 2027 | Dec 30, 2026 | 0.36 | — | — | — |
| Oct 28, 2026 | Sep 30, 2026 | 0.2145 | 0.34 | +0.13 | +58.51% |
| Jul 29, 2026 | Jun 30, 2026 | 0.1544 | 0.16 | +0.01 | +3.63% |
| Apr 29, 2026 | Mar 31, 2026 | 0.06 | 0.08 | +0.02 | +33.33% |
| Feb 18, 2026 | Dec 31, 2025 | 0.35 | 0.32 | -0.03 | -8.57% |
| Oct 29, 2025 | Sep 30, 2025 | 0.16 | 0.18 | +0.02 | +12.50% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 2, 2026 | HC Wainwright & Co. | down | Buy | Neutral |
| Oct 29, 2026 | JP Morgan | main | Neutral | Neutral |
| Oct 29, 2026 | Citigroup | main | Buy | Buy |
| Oct 29, 2026 | RBC Capital | main | Outperform | Outperform |
| Oct 29, 2026 | Wells Fargo | main | Equal-Weight | Equal-Weight |
| Oct 7, 2026 | Barclays | init | — | Overweight |
About Bausch + Lomb Corporation
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lenses that are indicated for therapeutic use and provide optical correction during healing. It also offers contact lens care products, eye vitamins, mineral supplements, and over-the-counter eye drops that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. The Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Country
- Canada
- Website
- bausch.com
News
Midterm Election Rally: 5 Relative Price Strength Stocks to Buy
Best Growth Stocks to Buy for November 5th
Bausch + Lomb: 3 Key Takeaways for Long-Term Investors
Why Bausch + Lomb (BLCO) Might be Well Poised for a Surge
Why Bausch + Lomb (BLCO) is a Top Momentum Stock for the Long-Term
BLCO vs. HQY: Which Stock Is the Better Value Option?
Best Momentum Stock to Buy for November 2nd
Why Bausch + Lomb (BLCO) is a Top Value Stock for the Long-Term
This Coinbase Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday
New Strong Buy Stocks for November 2nd
Your note
Sign in to keep a note on BLCO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| Appio (Thomas J) | Director or Senior Officer of 10% Security Holder | Exercise of rights | May 4, 2026 | 27,583 |
| Bailey (Ambrose Robert Douglas J.D.) | Senior Officer of Issuer | Exercise of rights | Apr 23, 2026 | 141,107 |
| Bausch Health Companies Inc. | 10% Security Holder of Issuer | Change in nature of ownership | Dec 8, 2025 | 0 |
| Bonnefoy (Luc) | Senior Officer of Issuer | Exercise of rights | Jun 11, 2026 | 35,441 |
| Eldessouky (Osama A) | Senior Officer of Issuer | Exercise of rights | May 4, 2026 | 200,998 |
| Hashad (Yehia) | Senior Officer of Issuer | Exercise of rights | May 4, 2026 | 107,523 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Icahn Carl C | 0.98% | 3,500,000 | 72.19M | Jun 29, 2026 |
| Deutsche Bank AG | 0.96% | 3,423,046 | 70.60M | Jun 29, 2026 |
| Oaktree Capital Management LP | 0.96% | 3,441,042 | 70.97M | Jun 29, 2026 |
| Shaw D.E. & Co., Inc. | 0.93% | 3,323,021 | 68.54M | Jun 29, 2026 |
| Davidson Kempner Capital Management LP | 0.88% | 3,158,972 | 65.15M | Jun 29, 2026 |
| Goldentree Asset Management LP | 0.74% | 2,660,508 | 54.87M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| T. Rowe Price High Yield Fund, Inc. | 0.23% | 837,050 | 17.26M | Aug 30, 2026 |
| TR PRICE-Price (T.Rowe) U.S. High Yield Trust | 0.13% | 454,220 | 9.37M | Jun 29, 2026 |
| T. ROWE PRICE Intl Fd.S, INC.-T. Rowe Price Dynamic Credit Fd. | 0.06% | 204,491 | 4.22M | Jun 29, 2026 |
| T. ROWE PRICE Inst. INCOME Fd.S, INC.-T. Rowe Price Inst. High Yield F | 0.06% | 218,211 | 4.50M | Aug 30, 2026 |
| Unified Series Trust-BALLAST SMALL/MID CAP ETF | 0.04% | 147,837 | 3.05M | Jun 29, 2026 |
| Gabelli Healthcare & WellnessRx Trust | 0.04% | 144,000 | 2.97M | Sep 29, 2026 |
